Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up
Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis.
You may also be interested in...
Analyst speculates that risk of pulmonary embolism for a higher unapproved dose of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.